Product image of Lanreotid Viatris (Lanreotide) supplied by GNH India

Lanreotid Viatris

Active Ingredient:
Lanreotide
Origin:
EU

Lanreotid Viatris (Lanreotide)

Lanreotide, the active ingredient in Lanreotid Viatris, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control hormone excess in patients with acromegaly and to manage tumor growth and hormone‑related symptoms in neuroendocrine tumors and carcinoid syndrome.

GNH India supplies Lanreotid Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics across global markets worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lanreotide is used in endocrine‑related disorders that involve excess hormone secretion or neuroendocrine tumor activity.

  • Acromegaly: reduces growth hormone and IGF‑1 levels, improving disease control.
  • Gastroenteropancreatic neuroendocrine tumors: inhibits tumor growth and hormone secretion, stabilizing disease.
  • Carcinoid syndrome: lessens flushing and diarrhea by blocking serotonin and other vasoactive substances.

How It Works

  • Lanreotide binds with high affinity to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5) on target cells. This interaction inhibits adenylate cyclase activity, reduces calcium influx, and suppresses secretion of growth hormone, insulin, glucagon, and various gastrointestinal peptides. In neuroendocrine tumor cells, receptor activation triggers antiproliferative signaling pathways, leading to decreased tumor cell proliferation and hormone production.

Side Effects

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain or erythema.
  • Diarrhea.
  • Nausea.
  • Abdominal cramps.
  • Headache.
  • Fatigue.

Serious or Rare Side Effects

  • Gallbladder disease (biliary sludge or stones).
  • Hyperglycemia or new‑onset diabetes.
  • Pancreatitis.
  • Severe allergic reactions (anaphylaxis, angioedema).
  • Cardiac arrhythmias.
  • Severe gastrointestinal perforation.

Precautions & Warnings

When prescribing Lanreotide, clinicians should consider several safety precautions to minimize risk.

  • Assess baseline glucose: monitor blood sugar as Lanreotide can affect glucose metabolism.
  • Evaluate gallbladder status: patients with gallstones may develop biliary complications.
  • Monitor for signs of pancreatitis: watch for abdominal pain and elevated enzymes.
  • Review cardiac history: caution in patients with known arrhythmias.
  • Adjust dose in renal or hepatic impairment: use with care in severe dysfunction.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

  • Concomitant use with cyclosporine: may increase lanreotide levels and risk of adverse effects.
  • Combined therapy with other somatostatin analogs: additive hormonal suppression can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents (insulin, sulfonylureas): monitor glucose as lanreotide may raise blood sugar.
  • CYP450 substrates metabolized by the liver: potential changes in drug concentrations.
  • Hormonal contraceptives: possible reduced efficacy due to altered hormone levels.
  • Digoxin: monitor for altered plasma levels.
  • Octreotide: overlapping mechanisms may require dose adjustments.

Frequently Asked Questions

Lanreotid Viatris, containing lanreotide, is indicated for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. In each case the drug helps to control excessive hormone secretion and, for tumors, can slow disease progression.

Lanreotide binds selectively to somatostatin receptors 2 and 5 on target cells. This binding blocks the release of several hormones—including growth hormone, insulin, glucagon, and gastrointestinal peptides—and activates antiproliferative pathways that reduce tumor cell growth and hormone output.

The dose of Lanreotid Viatris is individualized by the prescribing clinician based on the patient’s specific condition, disease severity, response to therapy, and any relevant comorbidities. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for lanreotide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Lanreotid Viatris (lanreotide) and other analogs such as octreotide share the same mechanism of receptor activation but differ in formulation and dosing frequency. Lanreotide is often administered as a long‑acting subcutaneous injection, allowing less frequent dosing compared with some short‑acting alternatives.

Lanreotid Viatris should be stored refrigerated at 2 °C to 8 °C. Keep the product in its original container, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose into the fatty tissue of the abdomen or thigh, following aseptic technique and the dosing schedule prescribed by the treating physician.

Serious adverse events include gallbladder disease (such as biliary sludge or stones), hyperglycemia or new‑onset diabetes, pancreatitis, severe allergic reactions (including anaphylaxis), cardiac arrhythmias, and rare gastrointestinal perforation. Patients should be monitored closely for these conditions.

Lanreotid Viatris is contraindicated in individuals with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is also advised for patients with severe hepatic or renal impairment, uncontrolled diabetes, or active gallbladder disease, where the risks may outweigh benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT